Pharma stocks, especially which have large exposure to United States, saw knee-jerk reaction on Friday after a media report indicated that US prosecutors are undertaking an investigation into the suspected price collusion.
Cadila Healthcare's second quarter earnings missed analysts' estimates on Wednesday with consolidated profit sinking 28.9 percent year-on-year to Rs 337.6 crore on slow revenue growth and operational pressure.
Pharma company Cadila Healthcare is expected to report a 2.3 percent growth in second quarter profit at Rs 399.83 crore and 0.7 percent rise in revenue at Rs 2,477.2 crore on yearly basis, according to average of estimates of analysts polled by CNBC-TV18.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.